Journal Article FZJ-2021-01724

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png
Functionalized lipid nanoparticles for subcutaneous administration of mRNA to achieve systemic exposures of a therapeutic protein

 ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;

2021
Nature Publ. Group New York, NY

Molecular Therapy / Nucleic Acids 24, 369 - 384 () [10.1016/j.omtn.2021.03.008]

This record in other databases:      

Please use a persistent id in citations:   doi:

Abstract: Lipid nanoparticles (LNPs) are the most clinically advanced delivery system for RNA-based drugs but have predominantly been investigated for intravenous and intramuscular administration. Subcutaneous administration opens the possibility of patient self-administration and hence long-term chronic treatment that could enable messenger RNA (mRNA) to be used as a novel modality for protein replacement or regenerative therapies. In this study, we show that subcutaneous administration of mRNA formulated within LNPs can result in measurable plasma exposure of a secreted protein. However, subcutaneous administration of mRNA formulated within LNPs was observed to be associated with dose-limiting inflammatory responses. To overcome this limitation, we investigated the concept of incorporating aliphatic ester prodrugs of anti-inflammatory steroids within LNPs, i.e., functionalized LNPs to suppress the inflammatory response. We show that the effectiveness of this approach depends on the alkyl chain length of the ester prodrug, which determines its retention at the site of administration. An unexpected additional benefit to this approach is the prolongation observed in the duration of protein expression. Our results demonstrate that subcutaneous administration of mRNA formulated in functionalized LNPs is a viable approach to achieving systemic levels of therapeutic proteins, which has the added benefits of being amenable to self-administration when chronic treatment is required.

Keyword(s): Health and Life (1st) ; Biology (2nd) ; Medicine (2nd) ; Soft Condensed Matter (2nd)

Classification:

Contributing Institute(s):
  1. JCNS-FRM-II (JCNS-FRM-II)
  2. Heinz Maier-Leibnitz Zentrum (MLZ)
  3. Neutronenstreuung (JCNS-1)
  4. JCNS-4 (JCNS-4)
Research Program(s):
  1. 6G4 - Jülich Centre for Neutron Research (JCNS) (FZJ) (POF4-6G4) (POF4-6G4)
  2. 632 - Materials – Quantum, Complex and Functional Materials (POF4-632) (POF4-632)
Experiment(s):
  1. KWS-2: Small angle scattering diffractometer (NL3ao)

Appears in the scientific report 2021
Database coverage:
Medline ; Creative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND 4.0 ; DOAJ ; OpenAccess ; Article Processing Charges ; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; DOAJ Seal ; Essential Science Indicators ; Fees ; IF >= 5 ; JCR ; PubMed Central ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection
Click to display QR Code for this record

The record appears in these collections:
Institute Collections > JCNS > JCNS-FRM-II
Document types > Articles > Journal Article
Institute Collections > JCNS > JCNS-4
Institute Collections > JCNS > JCNS-1
Workflow collections > Public records
Publications database
Open Access

 Record created 2021-04-13, last modified 2021-06-28


OpenAccess:
1-s2.0-S2162253121000792-main - Download fulltext PDF
manuscript_MolecularTherapyNucleicAcids - Download fulltext PDF
External link:
Download fulltextFulltext by OpenAccess repository
Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)